Key Benefits

• Duorandil is the first and only brand of nicorandil in India with U.S. Patent technology
  
  
• It is found to be 98.5% stable at room temperature in closed bottles and 97.8% stable at 61.5% relative humidity in open bottles
  
  
• A reduction in preload was apparent from a decrease in left ventricular end-diastolic pressure from 7.4 +/- 1.7 to -3.2 +/- 1.5 mm Hg.
  
  
• Nicorandil produced marked reductions in total peripheral resistance (19%)
  
  
• Aortic blood pressures with decreases in systolic pressure of 34%
  
  
• In diastolic pressure of 21%
  
  
• Nicorandil has a coronary vasodilating effect as well as a balanced peripheral action that leads to decreases in both preload and afterload
  
  
• Nicorandil is an effective and potent antianginal agent at a dose of 10-40 mg, which in monotherapy controls 69-80% of patients with stable chronic angina.
  
  
• Nicorandil provides a useful alternative to existing antianginal agents in the long-term management of patients with angina pectoris.

Indications

• Chronic Stable Angina